ESMO Open

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

ESMO Open
Jun 15, 2025, 06:09 | Insight
ESMO Open Shared 2025 Study Linking KRAS Variants to Therapeutic Outcomes in Biliary Tract Cancers
ESMO Open shared a post on X: "Association of KRAS variants with survival and therapeutic…
Jun 13, 2025, 07:28 | Science
QoL Findings from PALLAS Trial are Published in ESMO Open - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X about a paper by M.J. Naughton…
Jun 12, 2025, 09:55 | Blog
Financial toxicity and socioeconomic impact of cancer in Europe
ESMO Open shared a post on X: "Financial toxicity and socioeconomic impact of cancer in…
May 30, 2025, 00:26 | Insight
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer - ESMO Open
ESMO Open shared a post on X: "Efficacy and safety of larotrectinib as first-line treatment…
May 10, 2025, 13:57 | Blog
David Tougeron Introduces ENGIC – A New European Network for GI Cancers
David Tougeron, Professor at Poitiers University Hospital, shared a post on LinkedIn: "What is ENGIC?…
May 5, 2025, 13:03 | Science
Multicenter Analysis of High-Dose Chemotherapy Regimens For The Treatment of Patients With Refractory or Recurrent GCTs
ESMO Open shared a post on X: "Multicenter analysis of high-dose chemotherapy regimens for the…
May 2, 2025, 09:14 | Blog
ESMO Open - Tumor-Informed ctDNA Assay for Recurrence Prediction in Locally Advanced SCCHN
ESMO Open posted on X: "Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell…
Apr 13, 2025, 08:56 | Science
Gabor Liposits: Representation of GeriOnc in cancer care guidelines in Europe
Gabor Liposits, Senior consultant of Clinical Oncology at Regional Hospital Gødstrup, shared a post on…
Apr 10, 2025, 15:53 | Science
Aleix Prat: Prevalence and clinical impact of germline pathogenic variants in breast cancer
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a…
Apr 7, 2025, 11:42 | Science
Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study
Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO),…
Apr 6, 2025, 14:19 | Insight
Benefit of olaparib maintenance in 140 patients with ovarian cancer - ESMO Open
ESMO Open shared a post on X about a recent paper by Claudia Marchetti et…
Apr 2, 2025, 11:04 | Science
Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial
ESMO Open shared the post on X: "Exploratory analysis on elderly (>65yrs) patients enrolled in…
Mar 26, 2025, 18:03 | Blog
Molecular tumour board in gastrointestinal cancers
ESMO Open shared a post on X about a recent paper by L. Boscolo Bielo et al. published…
Mar 21, 2025, 07:37 | Blog
Erick Saldanha: How we treat patients with metastatic uveal melanoma
Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a…
Mar 9, 2025, 14:19 | Insight
Farah Tarek Shaalan: Knowledge and attitude toward cancer clinical trials in the Middle East and North Africa
Farah Tarek Shaalan, Medical Oncology Resident at National Cancer Institute - Cairo University, shared a…
Feb 27, 2025, 12:50 | Blog
Frequency, Clinical Features, and Functional Analysis of the PALB2 c.3350+5G>A Germline Pathogenic Variant
ESMO Open shared an article led by M.-C. Kang on X about the frequency, clinical…
Jan 29, 2025, 18:10 | Blog
January highlights from the ESMO portfolio - Elsevier Oncology
Elsevier Oncology shared a post on LinkedIn: "See this month’s highlights from the ESMO -…
Jan 25, 2025, 05:02 | Insight
HER2DX in HER2+ Inflammatory Breast Cancer: Correlative insights and comparative analysis
Dana-Farber’s Breast Oncology Center shared a post on X about a recent paper by F.…
Jan 19, 2025, 22:56 | Science
Bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab in pleural mesothelioma
Jarushka Naidoo, Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University, shared…
Jan 19, 2025, 14:07 | Insight
Aleix Prat: Utility of the HER2DX genomic assay in predicting pCR in HER2+ stage III IBC
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a…
Jan 19, 2025, 07:52 | Science
Paolo Tarantino: What’s distinct about Breast cancers with ERBB2?
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper…
Jan 15, 2025, 16:26 | Insight
An IGG gene signature links to longevity in breast cancer survivors - ESMO Open
ESMO Open shared a post on X about a recent paper by L. Angelats et…
Jan 14, 2025, 13:22 | Science
Aleix Prat: How immune fitness can provide valuable insights in breast cancer
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a…
Dec 7, 2024, 01:42 | Blog
Toni Choueiri: Excited to share the results of FRACTION-RCC
Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer…
Dec 4, 2024, 08:01 | Insight
Federica Giugliano: Characteristics and treatment patterns of patients with high risk HR+ BC in CANTO cohort
Federica Giugliano, ESMO Translational Research Fellow at Gustave Roussy, shared a post on X: “Published…
Nov 11, 2024, 22:39 | Insight
Erman Akkus: Surrogacy in esophageal cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a…
Nov 10, 2024, 16:37 | Insight
Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer
A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by…
Oct 26, 2024, 07:02 | Blog
Adolescent and young adult female cancer burden from 1990 to 2021
Yüksel Ürün shared a post on X: ''Adolescent and young adult (AYA) female cancers are…
Oct 23, 2024, 14:20 | Blog
Angelica Petrillo: Recently published key meta-analyses about ICIs in gastric cancer
Angelica Petrillo, Medical Doctor at Ospedale del Mare Napoli, shared a post by Arndt Vogel…
Oct 22, 2024, 14:41 | Insight
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma, summarised by Arndt Vogel
Arndt Vogel, Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School,…
Oct 20, 2024, 13:01 | Insight
Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma
Alberto Giovanni Leone, HIV/Oncology Fellow at Chelsea and Westminster Hospital NHS Foundation Trust, shared a post…
Oct 14, 2024, 11:40 | Insight
Characteristics and clinical outcomes of Breast Cancer in young BRCA carriers
Dana-Farber’s Breast Oncology Center shared a post on X: “New study now out in ESMO…
Oct 10, 2024, 15:57 | Insight
New ESMO Open editorial on Immunotherapy in breast cancer
ESMO Open shared a recent article by Paola Zagami on X: "Immunotherapy in the treatment landscape…
Oct 9, 2024, 07:16 | Blog
Diego Prost: The outcome with different agents in recurrent or advanced salivary cancer patients
Diego Prost, Medical oncologist and Neuro-oncology fellow at Pitié-Salpêtrière University Hospital, shared a post on X:…
Sep 21, 2024, 09:35 | Blog
Elisa Agostinetto: Characteristics and clinical outcomes of breast cancer
Elisa Agostinetto shared a post on X, about recent paper published in ESMO Open: Characteristics…
Sep 14, 2024, 09:44 | Societies
Key factors in promoting Professional Wellbeing of the Healthcare Workforce - ESMO
European Society for Medical Oncology(ESMO) shared a post on LinkedIn: "What are the key factors in…
Sep 12, 2024, 10:29 | Career
John Haanen Honored with 2024 ESMO Lifetime Achievement Award
John Haanen was recently awarded the 2024 ESMO Lifetime Achievement Award. John B.A.G. Haanen is…
Sep 9, 2024, 14:16 | Blog
Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions
Tom Powles shared a post on X, about recent paper published in ESMO Open: The…
Sep 6, 2024, 11:25 | Insight
Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC
Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…
Sep 4, 2024, 05:57 | Insight
Maria Lucia Reale: MET exon 14 skipping mutations in NSCLC
Maria Lucia Reale, Medical Oncologist at Vito Fazzi Hospital Company, shared on X: “Just out…
Sep 2, 2024, 17:22 | Insight
Carmine Valenza: The role of gBRCA-PV in post-PARPi myeloid neoplasms, in patients with ovarian cancer
Carmine Valenza, MPH Student at Harvard T.H. Chan School of Public Health, shared a post…
Sep 1, 2024, 15:03 | Blog
ESMO is seeking a new Editor-in-Chief to ESMO Open
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is seeking…
Aug 28, 2024, 14:41 | Insight
Targeting HER2-low gastric cancer, summary by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared a recent article…
Aug 24, 2024, 13:01 | Insight
Gabor Liposits: Geriatric assessment and management in older adults with cancer
Gabor Liposits, Senior consultant of Clinical Oncology at Regionshospitalet Gødstrup, shared on LinkedIn: "Hot of…
Aug 17, 2024, 19:56 | Insight
Oncotype DX Colon Recurrence Score in stage II colon cancer, summary by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara Üniversitesi Tıp Fakültesi, a post on X: "Oncotype…
Aug 12, 2024, 12:24 | Blog
Adjuvant chemotherapy schedules for breast cancer according to BMI
Marco Tagliamento, Medical oncologist at Ospedale Policlinico San Martino, shared a post on X: "Congrats…
Aug 8, 2024, 05:32 | Blog
Vivek Subbiah: Embracing novel technologies for a progressive health system
Vivek Subbiah shared a post on LinkedIn: "Hot off the press Special communication article just…
Jul 11, 2024, 14:28 | Blog
Alice Avancini: Exercise promotion in cancer by the oncologists
Kathryn Schmitz, Oncology researcher at Pitt’s School of Medicine and the director of UPMC Hillman’s…
Jul 4, 2024, 14:15 | Insight
Evolution of HR+/HER2- breast cancer during exposure to neoadjuvant chemotherapy and endocrine treatment
ESMO Open shared a post on X: "Hot off the press: Francesco Schettini et al.…
Jul 2, 2024, 15:04 | Blog
Francesco Schettini: Molecular changes induced by neoadjuvant CT and ET in breast cancer
Francesco Schettini, Medical Oncologist at the Breast Unit of the Hospital Clinic of Barcelona and Postdoc…
Jun 26, 2024, 15:13 | Blog
Toni Choueiri: Our new IMDC paper in ESMO Open led by Kosuke Takemura
Toni Choueiri shared a post by Kosuke Takemura, Staff Urologist at Ganken Hospital, on X: "Our new…
Jun 23, 2024, 11:13 | Blog
The new Impact Factor for ESMO Open has just been released
ESMO Open shared on X: "The new Impact Factor for ESMO Open has just been…
Jun 19, 2024, 12:19 | Blog
Oncology Advance - See this month’s highlights from the ESMO portfolio
Oncology Advance shared a post on X: "See this month’s highlights from the ESMO portfolio. Featured…
Jun 15, 2024, 16:02 | Dialogues
Oncodaily Talks: Dialogue with Giuseppe Curigliano, hosted by Chandler Park
OncoDaily Talks gathers people worldwide to discuss challenges in cancer care. We share creative solutions…
Jun 14, 2024, 16:10 | Insight
Ghassan Abou-Alfa on a paper by Arndt Vogel et al.
Ghassan Abou-Alfa, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on…
Jun 10, 2024, 10:08 | Societies
Vivek Subbiah: I endorse Dr. Giuseppe Curigliano for ESMO President 2027-28
Vivek Subbiah shared on X: "The elections for the ESMO President 2027-2028 are happening, its…
Jun 9, 2024, 01:38 | Insight
Stephen V Liu reflects on OS from PACIFIC-R
Stephen V Liu shared the following insight on X: "OS from PACIFIC-R: real-world outcomes with…
Jun 7, 2024, 11:07 | Blog
Paolo Tarantino: Grateful to be part of the ESMO Open team
Paolo Tarantino shared a post by Giuseppe Curigliano on LinkedIn: "Grateful to be part of the…
May 25, 2024, 07:41 | Insight
Paolo Tarantino: I’m extremely excited to support Giuseppe Curigliano for the next ESMO Presidential Elections!
Paolo Tarantino shared on LinkedIn: “I’m extremely excited to support Giuseppe Curigliano for the next…
May 24, 2024, 00:42 | Societies
Vivek Subbiah wholeheartedly supports and endorses Dr. Giuseppe Curigliano for ESMO President 2027-28
Vivek Subbiah shared on X: "Exciting news! The elections for the ESMO President 2027-2028 are…
May 23, 2024, 14:29 | Societies
The names of the candidates running for the ESMO Presidency 2027-2028 have been announced
The names of the candidates running for the ESMO Presidency 2027-2028 have been announced. Find…
May 15, 2024, 04:35 | Blog
Paolo Tarantino: A pleasure to co-host the latest ESMO Open podcast with Giuseppe Curigliano
Paolo Tarantino shared a post by ESMO - European Society for Medical Oncology on LinkedIn, adding:…
May 7, 2024, 06:28 | Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
May 6, 2024, 13:19 | Blog
Jon Lim: Some real challenges faced by oncologists in pursuing postgrad degrees
Jon Lim, Medical Oncologist and Postdoctoral Clinical Fellow at The Francis Crick Institute, posted on…
Apr 28, 2024, 16:53 | Blog
Paolo Tarantino: Unmissable editorial on the current status and next steps for studying and treating brain metastases in breast oncology
Paolo Tarantino shared a post by ESMO Open, on X: "Unmissable editorial on the current status…
Apr 28, 2024, 12:38 | Insight
Piotr Wysocki: Combined treatment (TKI+ICI) does not benefit favorable-risk mRCC patients
Piotr Wysocki recently shared on LinkedIn: "For several years, combined therapy based on the administration of…
Apr 25, 2024, 00:51 | Insight
New Paper Alert! Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma Authors: T. Powles,…
Apr 19, 2024, 06:47 | Positive
Editor Spotlight this week is Susana Banerjee - ESMO Open
ESMO Open shared on X: “Our Editor Spotlight this week is Susana Banerjee, ESMO Open…
Apr 17, 2024, 13:11 | Insight
New Paper Alert! Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal Cancer: A Real-World Analysis
New Paper Alert: Exploring Treatment Strategies After Progression to BRAF V600E-Targeted Therapy in Metastatic Colorectal…
Apr 16, 2024, 00:17 | Blog
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn: "In our latest…
Apr 11, 2024, 17:37 | Societies
Our Editor Spotlight this week is John B. Haanen, editor for immunotherapy - ESMO Open
ESMO Open shared a post on X: “Our Editor Spotlight this week is John B.…
Mar 31, 2024, 14:36 | Insight
Nazik Hammad: First systematic review on cancer workforce
Nazik Hammad posted on LinkedIn: "1st systematic review on cancer workforce. 1st lesson: quantity is not…
Mar 23, 2024, 14:45 | Insight
Article summaries by Erman Akkus: BMI and cancer prognosis and billiary tract cancer
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X/Twitter: 1. ''BMI, weight…
Mar 21, 2024, 10:54 | Insight
The Swedish SCAN-B cohort, the HER2DX risk-score was found significantly associated with OS after adjustment for clinical variables and treatment regimen - ESMO Open
ESMO Open posted on X: "Hot off the press: among 757 patients with early HER2+ breast…
Mar 13, 2024, 23:46 | Blog
Guilherme Nader Marta: Our meta-analysis looking at the prognostic value of ctDNA in early breast cancer is now out at ESMO Open
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn: “Our meta-analysis looking…
Mar 8, 2024, 19:21 | Societies
Our Editor Spotlight this week is Chiara Cremolini - ESMO Open
ESMO Open Journal announced on their X/Twitter page: "Our Editor Spotlight this week is Chiara…
Feb 26, 2024, 10:49 | Blog
Our Editor Spotlight this week is Solange Peters - ESMO Open
The Open Access journal of ESMO shared on their X/Twitter: ''Our Editor Spotlight this week is…
Feb 8, 2024, 17:54 | Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Nov 19, 2023, 00:17 | Blog
Stephanie Graff: Another brilliant editor-in-chief announcement from The European Society for Medical Oncology, this time for ESMO Open
Stephanie Graff shared the following on Twitter: “Another brilliant editor-in-chief announcement from The European Society…
Nov 11, 2023, 12:49 | Blog
Benedikt Westphalen: CUPISCO is out in ESMO Open
Benedikt Westphalen, Medical Lead of Precision Oncology at the Cancer Center Munich, shared on LinkedIn:…
Sep 7, 2023, 19:38 | Insight
Jarushka Naidoo: The secret to a long life as a clinician scientist is the same as a long marriage.
Quoting Jarushka Naidoo, a Professor of Medical Oncology at the Royal College of Surgeons in Ireland…
All: 81 Posts: 1 - 100
Special Coverage